Effect of Probiotics in Treatment of Minimal Hepatic Encephalopathy (MHE) and Health Related Quality of Life (MHE)
Primary Purpose
Chronic Liver Disease, Hepatic Encephalopathy
Status
Completed
Phase
Phase 2
Locations
India
Study Type
Interventional
Intervention
VSL#3
Lactulose
Sponsored by
About this trial
This is an interventional treatment trial for Chronic Liver Disease
Eligibility Criteria
Inclusion Criteria:
- All the patients with Chronic Liver Disease or Minimal Hepatic Encephalopathy (without overt hepatic encephalopathy) aged between 15 to 80 years of both the genders would be enrolled consecutively.
Exclusion Criteria:
- Patients with overt hepatic encephalopathy
- Active medical co-morbidities like CHD, chronic respiratory disease, chronic renal disease, malignancies, diabetes etc
- Malignancy
- History of taking lactulose or probiotics or antibiotics, in the past 6 weeks
- Presence of other neurological or psychiatric disorder
- Patients who underwent shunt surgery for portal hypertension
- History of taking medicines likely to interfere with psychometric performance
- History of GI hemorrhage or spontaneous bacterial peritonitis during the past 6 weeks
- Presence of mature cataracts and diabetic retinopathy
- Refused to participate in the study
Sites / Locations
- Dept. of Gastroenterology and H.N.U., All India Institute of Medical Sciences
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
VSL#3
Lactulose
Arm Description
30-60 ml of lactulose per day (2 months) to ensure 2-3 soft stools
Outcomes
Primary Outcome Measures
To compare the effect of probiotics and lactulose based on normalization of the abnormal test parameters, Neuropsychometric tests, P3ERP, EEG, venous ammonia levels, Development of overt encephalopathy and other complications and HRQOL
Secondary Outcome Measures
Full Information
NCT ID
NCT01008293
First Posted
November 4, 2009
Last Updated
June 3, 2013
Sponsor
CD Pharma India Pvt. Ltd.
Collaborators
Indian Council of Medical Research, All India Institute of Medical Sciences, New Delhi
1. Study Identification
Unique Protocol Identification Number
NCT01008293
Brief Title
Effect of Probiotics in Treatment of Minimal Hepatic Encephalopathy (MHE) and Health Related Quality of Life
Acronym
MHE
Official Title
Health Related Quality of Life in Patient With Chronic Liver Disease and Effect of Probiotics in the Treatment of MHE and Health Related Quality of Life
Study Type
Interventional
2. Study Status
Record Verification Date
June 2013
Overall Recruitment Status
Completed
Study Start Date
October 2009 (undefined)
Primary Completion Date
June 2012 (Actual)
Study Completion Date
October 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
CD Pharma India Pvt. Ltd.
Collaborators
Indian Council of Medical Research, All India Institute of Medical Sciences, New Delhi
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study is a randomized, open, parallel group, active comparator, single center trial. Objectives of the study are hereby given below:
To study the health related quality of life (HRQOL) in patients with chronic liver disease.
To assess the prevalence of minimal hepatic encephalopathy (MHE) in patients with chronic liver disease and assessment of HRQOL in patients with MHE.
To compare the effect of probiotics and lactulose in the treatment of MHE
To assess the effect of probiotics and lactulose on the HRQOL in patients with MHE.
Detailed Description
The study design would comprise of two parts
Part I: Cross sectional study: This part would comprise of the assessment of HRQOL in patients with CLD
All the consecutive patients diagnosed as CLD would be enrolled in the study. All these patients would be enrolled from the liver clinics of the department of gastroenterology and those admitted in the gastroenterology ward at AIIMS.
Alcohol would be considered to be the cause of CLD, if the patient regularly consumed ≥80g/d of alcohol for five years
The staging of cirrhosis would be done according to the Child Pugh classification: A, B and C
The causes of CLD would be divided into:- viral hepatitis, alcohol, viral hepatitis combining with alcohol and miscellaneous causes
Part II: Prospective randomized controlled trial: In this part the outcome of lactulose and probiotic therapy in the treatment of MHE and its effect on the HRQOL will be compared.
All the consecutive patients with CLD without overt encephalopathy would be screened for MHE.
All these patients would be enrolled from the liver clinics and the gastroenterology ward, AIIMS.
The diagnosis of MHE would be based on abnormal psychometric tests (NCT-A and NCT-B or FCT-A and FCT-B) and /or abnormal P300 auditory event related potentials.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Liver Disease, Hepatic Encephalopathy
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
120 (Actual)
8. Arms, Groups, and Interventions
Arm Title
VSL#3
Arm Type
Experimental
Arm Title
Lactulose
Arm Type
Active Comparator
Arm Description
30-60 ml of lactulose per day (2 months) to ensure 2-3 soft stools
Intervention Type
Drug
Intervention Name(s)
VSL#3
Intervention Description
VSL#3 (2 capsules bid.for 2 months, Each containing 112.5 billion viable lyophilized bacteria). Each capsule contains 4 strains of Lactobacillus (L. casei, L. plantarum, L. acidophilus, and L. delbrueckii subsp. bulgaricus), 3 strains of Bifidobacterium (B. longum, L. breve, and B. infantis), and 1 strain of Streptococcus salivarius subsp. thermophilus (designated hereafter as S. thermophilus)
Intervention Type
Drug
Intervention Name(s)
Lactulose
Other Intervention Name(s)
Duphalac
Intervention Description
30-60 ml of lactulose per day for 2 months to ensure 2-3 soft stools.
Primary Outcome Measure Information:
Title
To compare the effect of probiotics and lactulose based on normalization of the abnormal test parameters, Neuropsychometric tests, P3ERP, EEG, venous ammonia levels, Development of overt encephalopathy and other complications and HRQOL
Time Frame
2 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
15 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
All the patients with Chronic Liver Disease or Minimal Hepatic Encephalopathy (without overt hepatic encephalopathy) aged between 15 to 80 years of both the genders would be enrolled consecutively.
Exclusion Criteria:
Patients with overt hepatic encephalopathy
Active medical co-morbidities like CHD, chronic respiratory disease, chronic renal disease, malignancies, diabetes etc
Malignancy
History of taking lactulose or probiotics or antibiotics, in the past 6 weeks
Presence of other neurological or psychiatric disorder
Patients who underwent shunt surgery for portal hypertension
History of taking medicines likely to interfere with psychometric performance
History of GI hemorrhage or spontaneous bacterial peritonitis during the past 6 weeks
Presence of mature cataracts and diabetic retinopathy
Refused to participate in the study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Y K Joshi, Prof.
Organizational Affiliation
All India Institute of Medical Sciences, New Delhi
Official's Role
Principal Investigator
Facility Information:
Facility Name
Dept. of Gastroenterology and H.N.U., All India Institute of Medical Sciences
City
New Delhi
State/Province
Delhi
ZIP/Postal Code
110029
Country
India
12. IPD Sharing Statement
Learn more about this trial
Effect of Probiotics in Treatment of Minimal Hepatic Encephalopathy (MHE) and Health Related Quality of Life
We'll reach out to this number within 24 hrs